Your browser doesn't support javascript.
loading
Host chemokine signature as a biomarker for the detection of pre-cancerous cervical lesions.
Bhatia, Ramya; Kavanagh, Kim; Stewart, June; Moncur, Sharon; Serrano, Itziar; Cong, Duanduan; Cubie, Heather A; Haas, Juergen G; Busby-Earle, Camille; Williams, Alistair R W; Howie, Sarah E M; Cuschieri, Kate.
Afiliação
  • Bhatia R; Human Papillomavirus Research Group, Division of Pathology, University of Edinburgh, Edinburgh, United Kingdom.
  • Kavanagh K; Department of Mathematics and Statistics, Strathclyde University, Glasgow, United Kingdom.
  • Stewart J; Centre for Inflammation research, University of Edinburgh, Edinburgh, United Kingdom.
  • Moncur S; Centre for Inflammation research, University of Edinburgh, Edinburgh, United Kingdom.
  • Serrano I; Division of Infection and Pathway Medicine, University of Edinburgh, Edinburgh, United Kingdom.
  • Cong D; Centre for Inflammation research, University of Edinburgh, Edinburgh, United Kingdom.
  • Cubie HA; Global Health Academy, University of Edinburgh, Edinburgh, United Kingdom.
  • Haas JG; Division of Infection and Pathway Medicine, University of Edinburgh, Edinburgh, United Kingdom.
  • Busby-Earle C; Simpson Centre for Reproductive Health, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
  • Williams ARW; Simpson Centre for Reproductive Health, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
  • Howie SEM; Centre for Inflammation research, University of Edinburgh, Edinburgh, United Kingdom.
  • Cuschieri K; Scottish HPV Reference Laboratory, NHS Lothian, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
Oncotarget ; 9(26): 18548-18558, 2018 Apr 06.
Article em En | MEDLINE | ID: mdl-29719625
ABSTRACT

BACKGROUND:

The ability to distinguish which hrHPV infections predispose to significant disease is ever more pressing as a result of the increasing move to hrHPV testing for primary cervical screening. A risk-stratifier or "triage" of infection should ideally be objective and suitable for automation given the scale of screening.

RESULTS:

CCL2, CCL3, CCL4, CXCL1, CXCL8 and CXCL12 emerged as the strongest, candidate biomarkers to detect underlying disease [cervical intraepithelial neoplasia grade 2 or worse (CIN2+)]. For CIN2+, CCL2 had the highest area under the curve (AUC) of 0.722 with a specificity of 82%. A combined biomarker panel of six chemokines CCL2, CCL3, CCL4, CXCL1, CXCL8, and CXCL12 provides a sensitivity of 71% and specificity of 67%.

CONCLUSION:

The present work demonstrates that the levels of five chemokine-proteins are indicative of underlying disease. We demonstrate technical feasibility and promising clinical performance of a chemokine-based biomarker panel, equivalent to that of other triage options. Further assessment in longitudinal series is now warranted.

METHODS:

A panel of 31 chemokines were investigated for expression in routinely taken archived and prospective cervical liquid based cytology (LBC) samples using Human Chemokine Proteomic Array kit. Nine chemokines were further validated using Procartaplex assay on the Luminex platform.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article